<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Immatics Nv — News on 6ix</title>
<link>https://6ix.com/company/immatics-nv</link>
<description>Latest news and press releases for Immatics Nv on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/immatics-nv" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683583a278dffbe2df0fcc70.webp</url>
<title>Immatics Nv</title>
<link>https://6ix.com/company/immatics-nv</link>
</image>
<item>
<title>Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting</title>
<link>https://6ix.com/company/immatics-nv/news/immatics-announces-four-upcoming-oral-presentations-across-its-clinical-cell-therapy-and-bispecific-portfolio-at-2026-asco-annual-meeting-1</link>
<guid isPermaLink="true">https://6ix.com/company/immatics-nv/news/immatics-announces-four-upcoming-oral-presentations-across-its-clinical-cell-therapy-and-bispecific-portfolio-at-2026-asco-annual-meeting-1</guid>
<pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
<description>Houston, Texas and Tuebingen, Germany, April 21, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of</description>
</item>
<item>
<title>PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma</title>
<link>https://6ix.com/company/immatics-nv/news/prame-directed-cell-therapy-using-immatics-tcr-induces-deep-and-durable-remission-in-pediatric-patient-with-advanced-metastatic-nephroblastoma</link>
<guid isPermaLink="true">https://6ix.com/company/immatics-nv/news/prame-directed-cell-therapy-using-immatics-tcr-induces-deep-and-durable-remission-in-pediatric-patient-with-advanced-metastatic-nephroblastoma</guid>
<pubDate>Fri, 17 Apr 2026 19:00:00 GMT</pubDate>
<description>Individual experimental treatment attempt at Hopp Children’s Cancer Center Heidelberg (KiTZ) and Heidelberg University Hospital (UKHD) using a TCR T-cell therapy engineered with a PRAME-directed TCR provided by Immatics 17-year-old adolescent with bulky, rapidly progressing nephroblastoma and no remaining treatment options achieved deep remission, including marked regression of liver, lung and brain metastases; response ongoing at 6 months of follow-up PRAME is a multi-pediatric cancer target, a</description>
</item>
<item>
<title>Immatics Announces Full Year 2025 Financial Results and Business Update</title>
<link>https://6ix.com/company/immatics-nv/news/immatics-announces-full-year-2025-financial-results-and-business-update-13</link>
<guid isPermaLink="true">https://6ix.com/company/immatics-nv/news/immatics-announces-full-year-2025-financial-results-and-business-update-13</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma</description>
</item>
<item>
<title>Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress</title>
<link>https://6ix.com/company/immatics-nv/news/immatics-presents-ima203cd8-prame-cell-120000193</link>
<guid isPermaLink="true">https://6ix.com/company/immatics-nv/news/immatics-presents-ima203cd8-prame-cell-120000193</guid>
<pubDate>Thu, 11 Dec 2025 12:00:00 GMT</pubDate>
<description>IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor activity in advanced solid tumors after one-time infusion of IMA203CD8 at a low median dose during ongoing dose escalation, including deep and durable responses Promising dose-dependent clinical signal in ovarian carcinoma supports the strategy to position IMA203CD8 in the tumor-agnostic setting of ad</description>
</item>
<item>
<title>Immatics Announces $125 Million Underwritten Offering</title>
<link>https://6ix.com/company/immatics-nv/news/immatics-announces-125-million-underwritten-110000322</link>
<guid isPermaLink="true">https://6ix.com/company/immatics-nv/news/immatics-announces-125-million-underwritten-110000322</guid>
<pubDate>Fri, 05 Dec 2025 11:00:00 GMT</pubDate>
<description>Houston, Texas and Tuebingen, Germany, December 05, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, announced today that it has agreed to sell 12,500,000 ordinary shares at $10.00 per share in an underwritten offering. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be $125 million. The offering is expected to</description>
</item>
<item>
<title>Immatics Announces Third Quarter 2025 Financial Results and Business Update</title>
<link>https://6ix.com/company/immatics-nv/news/immatics-announces-third-quarter-2025-120000203</link>
<guid isPermaLink="true">https://6ix.com/company/immatics-nv/news/immatics-announces-third-quarter-2025-120000203</guid>
<pubDate>Mon, 17 Nov 2025 12:00:00 GMT</pubDate>
<description>Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; interim and final analyses will occur in 2026 Anzu-cel (IMA203) PRAME Cell Therapy: One-time infusion continues to show strong clinical benefit and favorable tolerability in 16 patients with metastatic uveal melanoma in latest update on Phase 1b data presented at the ESMO 2025 Presidential Symposium: cORR of 67%, mDOR of 11.0 month</description>
</item>
<item>
<title>Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps</title>
<link>https://6ix.com/company/immatics-nv/news/immatics-achieves-clinical-proof-concept-120000932</link>
<guid isPermaLink="true">https://6ix.com/company/immatics-nv/news/immatics-achieves-clinical-proof-concept-120000932</guid>
<pubDate>Wed, 12 Nov 2025 12:00:00 GMT</pubDate>
<description>Company to host conference call and webcast today, November 12, at 8:30 am EST/2:30 pm CET IMA402 and IMA401 TCR Bispecifics showed favorable tolerability at RP2D as well as deep and durable responses in heavily pre-treated, last-line patients with a range of solid tumors IMA402 PRAME Bispecific at RP2D range resulted in a 30% cORR (6/20) across all indications, including 29% (4/14) in melanoma and 2/3 confirmed responses in ovarian carcinoma IMA401 MAGEA4/8 Bispecific at ≥1 mg resulted in a 25%</description>
</item>
<item>
<title>Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps </title>
<link>https://6ix.com/company/immatics-nv/news/immatics-achieves-clinical-proof-of-concept-of-its-next-generation-tcr-bispecific-tcerr-pipeline-with-data-on-ima402-prame-and-ima401-magea48-and-announces-next-development-steps</link>
<guid isPermaLink="true">https://6ix.com/company/immatics-nv/news/immatics-achieves-clinical-proof-of-concept-of-its-next-generation-tcr-bispecific-tcerr-pipeline-with-data-on-ima402-prame-and-ima401-magea48-and-announces-next-development-steps</guid>
<pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
<description>Company to host conference call and webcast today, November 12, at 8:30 am EST/2:30 pm CET IMA402 and IMA401 TCR Bispecifics showed favorable tolerability at</description>
</item>
<item>
<title>Immatics Appoints Amie Krause as Chief People Officer</title>
<link>https://6ix.com/company/immatics-nv/news/immatics-appoints-amie-krause-chief-110000631</link>
<guid isPermaLink="true">https://6ix.com/company/immatics-nv/news/immatics-appoints-amie-krause-chief-110000631</guid>
<pubDate>Mon, 27 Oct 2025 11:00:00 GMT</pubDate>
<description>Houston, Texas and Tuebingen, Germany, October 27, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Amie Krause as Chief People Officer (“CPO”) effective October 27, 2025. Ms. Krause brings more than 20 years of experience in shaping culture, leading organizational growth and aligning talent with business strategy, including across global biopharma</description>
</item>
<item>
<title>Immatics Appoints Venkat Ramanan as Chief Financial Officer</title>
<link>https://6ix.com/company/immatics-nv/news/immatics-appoints-venkat-ramanan-chief-110000404</link>
<guid isPermaLink="true">https://6ix.com/company/immatics-nv/news/immatics-appoints-venkat-ramanan-chief-110000404</guid>
<pubDate>Wed, 01 Oct 2025 11:00:00 GMT</pubDate>
<description>Houston, Texas and Tuebingen, Germany, October 1, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Venkat Ramanan, Ph.D., as Chief Financial Officer (“CFO”), effective immediately. Dr. Ramanan is a seasoned financial leader in the biopharmaceutical industry with over 25 years of experience at companies including Seagen, Gilead Sciences and Amgen. H</description>
</item>
<item>
<title>Immatics Announces Second Quarter 2025 Financial Results and Business Update</title>
<link>https://6ix.com/company/immatics-nv/news/immatics-announces-second-quarter-2025-110000355</link>
<guid isPermaLink="true">https://6ix.com/company/immatics-nv/news/immatics-announces-second-quarter-2025-110000355</guid>
<pubDate>Wed, 13 Aug 2025 11:00:00 GMT</pubDate>
<description>Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: One-time infusion continues to show favorable tolerability as well as strong anti-tumor activity and durability in 33 heavily pretreated patients with metastatic melanoma in data from a Phase 1b trial presented at the 2025 ASCO Annual Meeting: 56% cORR, 12.1 months mDOR at 13.4 months mFU, 6.1 months mPFS and 15.9 months mOS Anzu-cel (IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously tre</description>
</item>
<item>
<title>Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma</title>
<link>https://6ix.com/company/immatics-nv/news/immatics-ima203-prame-cell-therapy-120000270</link>
<guid isPermaLink="true">https://6ix.com/company/immatics-nv/news/immatics-ima203-prame-cell-therapy-120000270</guid>
<pubDate>Sat, 31 May 2025 12:00:00 GMT</pubDate>
<description>Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing deep and durable objective responses up to >2.5 years IMA203 PRAME cell therapy one-time infusion in all melanoma patients shows cORR of 56%; mDOR of 12.1 months at mFU of 13.4 months; mPFS of 6.1 months; mOS of 15.9 months Cutaneous melanoma subgroup post-checkpoint inhibitor shows cORR of 50%,</description>
</item>
<item>
<title>Immatics Announces First Quarter 2025 Financial Results and Business Update</title>
<link>https://6ix.com/company/immatics-nv/news/immatics-announces-first-quarter-2025-110000767</link>
<guid isPermaLink="true">https://6ix.com/company/immatics-nv/news/immatics-announces-first-quarter-2025-110000767</guid>
<pubDate>Tue, 13 May 2025 11:00:00 GMT</pubDate>
<description>IMA203 PRAME Cell Therapy: Randomized-controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing and expected to complete enrollment in 2026IMA203 PRAME Cell Therapy: Phase 1b clinical trial ongoing with updated data in metastatic melanoma with substantially longer follow-up and additional uveal melanoma patients to be presented in an oral presentation at the 2025 ASCO Annual Meeting IMA203CD8 PRAME Cell Therapy (GEN2): Phase 1a clinical trial in solid tumors ongoing with</description>
</item>
<item>
<title>Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting</title>
<link>https://6ix.com/company/immatics-nv/news/immatics-announces-upcoming-oral-poster-140000414</link>
<guid isPermaLink="true">https://6ix.com/company/immatics-nv/news/immatics-announces-upcoming-oral-poster-140000414</guid>
<pubDate>Wed, 23 Apr 2025 14:00:00 GMT</pubDate>
<description>Houston, Texas and Tuebingen, Germany, April 23, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming presentations on its lead cell therapy product candidate, IMA203 TCR T-cell therapy targeting PRAME, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 30 – June 3, 2025, in Chicago, Illinoi</description>
</item>
<item>
<title>Immatics Announces Full Year 2024 Financial Results and Business Update</title>
<link>https://6ix.com/company/immatics-nv/news/immatics-announces-full-2024-financial-110000527</link>
<guid isPermaLink="true">https://6ix.com/company/immatics-nv/news/immatics-announces-full-2024-financial-110000527</guid>
<pubDate>Thu, 27 Mar 2025 11:00:00 GMT</pubDate>
<description>Randomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine® IMA203 TCR-T (PRAME) in advanced melanoma patients; first patient randomized and enrollment continues as plannedACTengine® IMA203 TCR-T (PRAME): Phase 1b IMA203 data published in October 2024 demonstrated a confirmed ORR of 54%, 12.1 months mDOR, 6 months mPFS and OS not reached at a mFU time of 8.6 months in advanced melanoma patients; next data update on Phase 1b trial with extended follow-up planned in 2025 Second-generation</description>
</item>
<item>
<title>Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME</title>
<link>https://6ix.com/company/immatics-nv/news/immatics-announces-third-quarter-2024-financial-results-business-update-and-first-clinical-data-on-tcerr-ima402-targeting-prame</link>
<guid isPermaLink="true">https://6ix.com/company/immatics-nv/news/immatics-announces-third-quarter-2024-financial-results-business-update-and-first-clinical-data-on-tcerr-ima402-targeting-prame</guid>
<pubDate>Mon, 18 Nov 2024 05:00:00 GMT</pubDate>
<description>The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics</description>
</item>
<item>
<title>Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME</title>
<link>https://6ix.com/company/immatics-nv/news/immatics-announces-multiple-presentations-at-the-39th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc-on-tcr-t-therapy-candidates-targeting-prame</link>
<guid isPermaLink="true">https://6ix.com/company/immatics-nv/news/immatics-announces-multiple-presentations-at-the-39th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc-on-tcr-t-therapy-candidates-targeting-prame</guid>
<pubDate>Fri, 08 Nov 2024 05:00:00 GMT</pubDate>
<description>Two oral presentations and multiple posters on clinical andpreclinical-stage candidates to be presented at SITC, demonstratingthe strength of Immatics’ TCR-T</description>
</item>
<item>
<title>Immatics Announces Pricing of $150 Million Public Offering</title>
<link>https://6ix.com/company/immatics-nv/news/immatics-announces-pricing-of-dollar150-million-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/immatics-nv/news/immatics-announces-pricing-of-dollar150-million-public-offering</guid>
<pubDate>Thu, 10 Oct 2024 04:00:00 GMT</pubDate>
<description>Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the</description>
</item>
<item>
<title>Immatics Announces Proposed $150 Million Public Offering</title>
<link>https://6ix.com/company/immatics-nv/news/immatics-announces-proposed-dollar150-million-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/immatics-nv/news/immatics-announces-proposed-dollar150-million-public-offering</guid>
<pubDate>Thu, 10 Oct 2024 04:00:00 GMT</pubDate>
<description>Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the</description>
</item>
<item>
<title>Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial</title>
<link>https://6ix.com/company/immatics-nv/news/immatics-announces-updated-phase-1b-clinical-data-on-actenginer-ima203-tcr-t-targeting-prame-in-melanoma-patients-and-provides-update-on-upcoming-suprame-phase-3-trial</link>
<guid isPermaLink="true">https://6ix.com/company/immatics-nv/news/immatics-announces-updated-phase-1b-clinical-data-on-actenginer-ima203-tcr-t-targeting-prame-in-melanoma-patients-and-provides-update-on-upcoming-suprame-phase-3-trial</guid>
<pubDate>Thu, 10 Oct 2024 04:00:00 GMT</pubDate>
<description>Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST Company announces updated Phase 1b clinical data on ACTengine®</description>
</item>
</channel>
</rss>